JP2007520553A - 多微粒子o−デスメチルベンラファキシン塩およびその使用 - Google Patents

多微粒子o−デスメチルベンラファキシン塩およびその使用 Download PDF

Info

Publication number
JP2007520553A
JP2007520553A JP2006552145A JP2006552145A JP2007520553A JP 2007520553 A JP2007520553 A JP 2007520553A JP 2006552145 A JP2006552145 A JP 2006552145A JP 2006552145 A JP2006552145 A JP 2006552145A JP 2007520553 A JP2007520553 A JP 2007520553A
Authority
JP
Japan
Prior art keywords
formulation
odv
multiparticulate
formate
succinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006552145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520553A5 (cg-RX-API-DMAC7.html
Inventor
ディオリオ,クリストファー,リチャード
シャー,シィド,エム.
ファウジ,マーディ,ビー.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of JP2007520553A publication Critical patent/JP2007520553A/ja
Publication of JP2007520553A5 publication Critical patent/JP2007520553A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006552145A 2004-02-06 2005-01-25 多微粒子o−デスメチルベンラファキシン塩およびその使用 Withdrawn JP2007520553A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54238404P 2004-02-06 2004-02-06
PCT/US2005/002215 WO2005077340A1 (en) 2004-02-06 2005-01-25 Multiparticulate o-desmethylvenlafaxine salts and uses thereof

Publications (2)

Publication Number Publication Date
JP2007520553A true JP2007520553A (ja) 2007-07-26
JP2007520553A5 JP2007520553A5 (cg-RX-API-DMAC7.html) 2008-02-14

Family

ID=34860300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552145A Withdrawn JP2007520553A (ja) 2004-02-06 2005-01-25 多微粒子o−デスメチルベンラファキシン塩およびその使用

Country Status (21)

Country Link
US (1) US20050175698A1 (cg-RX-API-DMAC7.html)
EP (2) EP1711167A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007520553A (cg-RX-API-DMAC7.html)
KR (1) KR20060132891A (cg-RX-API-DMAC7.html)
CN (1) CN1917860A (cg-RX-API-DMAC7.html)
AR (1) AR050230A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005212166A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507372A (cg-RX-API-DMAC7.html)
CA (1) CA2554559A1 (cg-RX-API-DMAC7.html)
CR (1) CR8535A (cg-RX-API-DMAC7.html)
EC (1) ECSP066827A (cg-RX-API-DMAC7.html)
IL (1) IL177052A0 (cg-RX-API-DMAC7.html)
NO (1) NO20063963L (cg-RX-API-DMAC7.html)
PA (1) PA8622601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20050771A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006127437A (cg-RX-API-DMAC7.html)
SG (1) SG149894A1 (cg-RX-API-DMAC7.html)
SV (1) SV2005002008A (cg-RX-API-DMAC7.html)
TW (1) TW200528092A (cg-RX-API-DMAC7.html)
WO (1) WO2005077340A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200606526B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519326A (ja) * 2012-05-03 2015-07-09 シプラ・リミテッド 抗レトロウイルス組成物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
CA2368083A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
EA011451B1 (ru) 2001-02-12 2009-04-28 Уайт Новая соль сукцинат о-десметилвенлафаксина
WO2006070735A1 (ja) * 2004-12-27 2006-07-06 Astellas Pharma Inc. ソリフェナシンまたはその塩の安定な粒子状医薬組成物
ES2335919T3 (es) * 2005-03-31 2010-04-06 Wyeth Producto de combinacion de o-desmetilvenlafaxina y bazedosifeno, y sus usos.
EP1904046A4 (en) * 2005-07-06 2008-10-01 Sepracor Inc COMBINATIONS OF ESZOPICLON AND O-DESMETHYLVENLAFAXINE AND METHOD FOR THE TREATMENT OF MENOPAUSE AND HUMOR FLUCTUATIONS; ANXIETY AND COGNITIVE INTERFERENCE
US7595340B2 (en) 2005-07-15 2009-09-29 Wyeth Serotonin and norepinephrine reuptake inhibitor and uses thereof
TW200740427A (en) * 2005-07-15 2007-11-01 Wyeth Corp Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
EP1904434A2 (en) * 2005-07-15 2008-04-02 Wyeth a Corporation of the State of Delaware Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
US7687520B2 (en) 2005-07-15 2010-03-30 Wyeth Llc Serotonin and norepinephrine reuptake inhibitors and uses thereof
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
EP1870395A1 (en) 2006-06-19 2007-12-26 KRKA, D.D., Novo Mesto Process for preparation of o-desmethylvenlafaxine and its analogue
US20100210719A1 (en) * 2007-07-12 2010-08-19 Dr. Reddy's Laboratories Ltd. O-desmethylvenlafaxine
US20100330172A1 (en) * 2007-10-16 2010-12-30 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US20110046231A1 (en) * 2007-10-22 2011-02-24 Actavis Group Ptc Ehf Solid forms of (±)-o-desmethylvenlafaxine salts
EP2552419A2 (en) 2010-03-31 2013-02-06 Wockhardt Limited Modified release dosage form comprising desvenlafaxine or salts thereof
WO2012140577A1 (en) 2011-04-12 2012-10-18 Lupin Limited Modified release pharmaceutical compositions of desvenlafaxine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081496A (en) * 1959-10-15 1963-03-19 John F Moore Method of forming flexible sheets of cured foamed rubber
AT294000B (de) * 1965-01-11 1971-11-10 Diersch & Schroeder Verfahren zur Herstellung von Teppichen oder Läufern
US3885257A (en) * 1972-10-30 1975-05-27 Evans Ronald J P Pressure controlled resilient supporting structure
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4603445A (en) * 1983-09-09 1986-08-05 Span-America Medical Systems, Inc. Support pad and method of manufacture
US5099627A (en) * 1990-09-28 1992-03-31 Benjamin Obdyke Incorporated Ventilated roof construction and method
US5203703A (en) * 1991-08-27 1993-04-20 Schneiderman Marc J Deglutition training method and apparatus
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6162309A (en) * 1998-04-21 2000-12-19 Burlington Industries, Inc. Reinforced foam backed carpet
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
CA2368083A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
AU5738700A (en) * 1999-06-15 2001-01-02 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
US6863972B2 (en) * 2001-01-09 2005-03-08 Crane Plastics Company Llc Synthetic wood component having a foamed polymer backing
EA011451B1 (ru) * 2001-02-12 2009-04-28 Уайт Новая соль сукцинат о-десметилвенлафаксина
US20030152741A1 (en) * 2002-02-05 2003-08-14 Robbins Jeffrey L. Patterned polyurethane foam and a process for the production of tufted goods with patterned foam backing
US20030191347A1 (en) * 2002-03-28 2003-10-09 Rolf Keltjens Venlafaxine base
WO2003103603A2 (en) * 2002-06-10 2003-12-18 Wyeth Novel formate salt of o-desmethyl-venlafaxine
JP2004359665A (ja) * 2003-05-30 2004-12-24 Rohm & Haas Co 生体利用性増強剤を含有する治療組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519326A (ja) * 2012-05-03 2015-07-09 シプラ・リミテッド 抗レトロウイルス組成物

Also Published As

Publication number Publication date
CA2554559A1 (en) 2005-08-25
PA8622601A1 (es) 2005-10-28
IL177052A0 (en) 2006-12-10
SV2005002008A (es) 2005-11-04
EP1711167A1 (en) 2006-10-18
CR8535A (es) 2006-12-07
AU2005212166A1 (en) 2005-08-25
KR20060132891A (ko) 2006-12-22
BRPI0507372A (pt) 2007-07-10
NO20063963L (no) 2006-09-05
CN1917860A (zh) 2007-02-21
SG149894A1 (en) 2009-02-27
WO2005077340A1 (en) 2005-08-25
US20050175698A1 (en) 2005-08-11
RU2006127437A (ru) 2008-03-20
TW200528092A (en) 2005-09-01
ECSP066827A (es) 2006-11-24
PE20050771A1 (es) 2005-11-15
EP2052717A1 (en) 2009-04-29
AR050230A1 (es) 2006-10-11
ZA200606526B (en) 2010-03-31

Similar Documents

Publication Publication Date Title
US8557282B2 (en) Extended release compositions comprising as active compound venlafaxine hydrochloride
CN101977593B (zh) 包含弱碱性药物以及有机酸的给药系统
US20050175698A1 (en) Multiparticulate O-desmethylvenlafaxine salts and uses thereof
SK9899A3 (en) Tramadol multiple unit formulations
JP2009501233A (ja) バイオアベイラビリティーの高いo−デスメチルベンラファキシンスクシネートの経口用遅延放出投薬形態
JPH09500914A (ja) 粉末被覆経口投与剤形
CN101534792A (zh) 包含氧可酮的粒剂和口腔崩解片剂
JP2012516299A (ja) 有機化合物のガレヌス製剤
EP1711169B1 (en) Extended release coated minitablets of venlafaxine hydrochloride
CN1161112C (zh) 含氯雷他定和伪麻黄碱的药物胶囊组合物
WO2009057138A2 (en) Controlled release pharmaceutical compositions of tolterodine
JP2007520553A5 (cg-RX-API-DMAC7.html)
WO2010129689A1 (en) Milnacipran formulations
JP5919173B2 (ja) 徐放性塩酸アンブロキソール口腔内崩壊錠
MXPA06008933A (en) Multiparticulate o-desmethylvenlafaxine salts and uses thereof
KR20250110202A (ko) 변형-방출 실로도신 조성물 및 남성 피임 방법에서 이의 용도
OA22166A (en) Modified-Release Silodosin Compositions And Use Thereof In Methods For Male Contraception.
HK1091137B (en) Extended release coated minitablets of venlafaxine hydrochloride
HK1144393A (en) Extended release venlafaxine formulation
AU2014246617A1 (en) Multi-layered, multiple unit pharmaceutical compositions
CN101180039A (zh) 至少一种形式的文拉法辛的缓释组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071220

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101026